奕瑞科技(688301.SH):完成了CT探測器及子系統集成目標並送樣測試
格隆匯12月24日丨奕瑞科技(688301.SH)在投資者互動平台表示,根據QY Research 相關調研統計,2023年全球CT探測器市場銷售額達到了79億元,預計2030年將達到126億元,年複合增長率(CAGR)為6.9%。關於醫療CT探測器,目前公司已完成硫氧化釓閃爍體陶瓷(GOS)、準直器(ASG)、光電二極管(PD)等核心部件開發,結合定製的讀出芯片,完成了CT探測器及子系統集成目標並送樣測試,部分醫療CT用二維準直器也已完成研發及國內客户導入,進入量產銷售階段,同時公司正就光子計數探測器及模組進行開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.